Literature DB >> 26732278

Harpagophytum Procumbens Ethyl Acetate Fraction Reduces Fluphenazine-Induced Vacuous Chewing Movements and Oxidative Stress in Rat Brain.

Larissa Finger Schaffer1, Catiuscia Molz de Freitas2, Ana Paula Chiapinotto Ceretta1, Luis Ricardo Peroza2, Elizete de Moraes Reis1, Bárbara Nunes Krum2, Alcindo Busanello1, Aline Augusti Boligon3, Jéssie Haigert Sudati4, Roselei Fachinetto1,2, Caroline Wagner5,6.   

Abstract

Long-term treatment with fluphenazine is associated with manifestation of extrapyramidal side effects, such as tardive dyskinesia. The molecular mechanisms related to the pathophysiology of TD remain unclear, and several hypotheses, including a role for oxidative stress, have been proposed. Harpagophytum procumbens is an herbal medicine used mainly due to anti-inflammatory effects, but it also exhibits antioxidant effects. We investigated the effect of ethyl acetate fraction of H. procumbens (EAF HP) in fluphenazine-induced orofacial dyskinesia by evaluating behavioral parameters at different times (vacuous chewing movements (VCM's) and locomotor and exploratory activity), biochemical serological analyses, and biochemical markers of oxidative stress of the liver, kidney, cortex, and striatum. Chronic administration of fluphenazine (25 mg/kg, intramuscular (i.m) significantly increased the VCMs at all analyzed times (2, 7, 14, and 21 days), and this was inhibited by EAF HP (especially at a dose of 30 mg/kg). Fluphenazine decreased locomotion and exploratory activity, and EAF HP did not improve this decrease. Fluphenazine induced oxidative damage, as identified by changes in catalase activity and ROS levels in the cortex and striatum, which was reduced by EAF HP, especially in the striatum. In the cortex, EAF HP was protective against fluphenazine-induced changes in catalase activity but not against the increase in ROS level. Furthermore, EAF HP was shown to be safe, since affected serum biochemical parameters or parameters of oxidative stress in the liver and kidney. These findings suggest that the H. procumbens is a promising therapeutic agent for the treatment of involuntary oral movements.

Entities:  

Keywords:  Antioxidant; Antipsychotic; Devil’s claw; Harpagoside; Tardive dyskinesia

Mesh:

Substances:

Year:  2016        PMID: 26732278     DOI: 10.1007/s11064-015-1811-y

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  78 in total

Review 1.  The commercial harvest of devil's claw (Harpagophytum spp.) in southern Africa: the devil's in the details.

Authors:  Kristine M Stewart; David Cole
Journal:  J Ethnopharmacol       Date:  2005-09-14       Impact factor: 4.360

Review 2.  Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.

Authors:  Samer Alabed; Youssef Latifeh; Husam Aldeen Mohammad; Abdullah Rifai
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

3.  Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain.

Authors:  Marilise E Burger; Roselei Fachinetto; Gilson Zeni; João B T Rocha
Journal:  Pharmacol Biochem Behav       Date:  2005-07       Impact factor: 3.533

4.  Physicochemical properties of harpagoside and its in vitro release from Harpagophytum procumbens extract tablets.

Authors:  S Chrubasik; F Sporer; R Dillmann-Marschner; A Friedmann; M Wink
Journal:  Phytomedicine       Date:  2000-01       Impact factor: 5.340

5.  Vitamin E, lipids, and lipid peroxidation products in tardive dyskinesia.

Authors:  K Brown; A Reid; T White; T Henderson; S Hukin; C Johnstone; A Glen
Journal:  Biol Psychiatry       Date:  1998-06-15       Impact factor: 13.382

6.  Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.

Authors:  Raina M Rogoza; David F Fairfax; Paul Henry; Sevil N-Marandi; Rao F Khan; Suresh K Gupta; Ram K Mishra
Journal:  Synapse       Date:  2004-12-01       Impact factor: 2.562

7.  Bauhinia forficata prevents vacuous chewing movements induced by haloperidol in rats and has antioxidant potential in vitro.

Authors:  Luis Ricardo Peroza; Alcindo Busanello; Caroline Queiroz Leal; Jivago Röpke; Aline Augusti Boligon; Daiane Meinerz; Milena Libardoni; Margareth Linde Athayde; Roselei Fachinetto
Journal:  Neurochem Res       Date:  2013-02-02       Impact factor: 3.996

8.  Anandamide attenuates haloperidol-induced vacuous chewing movements in rats.

Authors:  Jivago Röpke; Alcindo Busanello; Caroline Queiroz Leal; Elizete de Moraes Reis; Catiuscia Molz de Freitas; Jardel Gomes Villarinho; Fernanda Hernandes Figueira; Carlos Fernando Mello; Juliano Ferreira; Roselei Fachinetto
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-04-18       Impact factor: 5.067

Review 9.  Hormetic dietary phytochemicals.

Authors:  Tae Gen Son; Simonetta Camandola; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2008-06-10       Impact factor: 3.843

10.  Selective increases in the cytokine, TNFalpha, in the prefrontal cortex of PCP-treated rats and human schizophrenic subjects: influence of antipsychotic drugs.

Authors:  G J Paterson; Y Ohashi; G P Reynolds; J A Pratt; B J Morris
Journal:  J Psychopharmacol       Date:  2006-02-14       Impact factor: 4.153

View more
  3 in total

1.  Alteration of Cytokines Levels in the Striatum of Rats: Possible Participation in Vacuous Chewing Movements Induced by Antipsycotics.

Authors:  Luis Ricardo Peroza; Larissa Finger Schaffer; Catiuscia Molz De Freitas; Caroline Queiroz Leal; Mayara Calegaro Ferrari; Marta Maria Frescura Duarte; Roselei Fachinetto
Journal:  Neurochem Res       Date:  2016-05-26       Impact factor: 3.996

2.  Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review.

Authors:  Haiyun Xu; Xiaoyin Zhuang
Journal:  Neuropsychiatr Dis Treat       Date:  2019-07-22       Impact factor: 2.570

Review 3.  Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies.

Authors:  Evangelia Eirini Tsermpini; Sara Redenšek; Vita Dolžan
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.